Novo-owned company sells former Boehringer project
The Swedish drug group Orexo, in which Novo Holdings holds one fourth of the shares, has sold a development program for anti-inflammatory drugs to a newly founded company in Stockholm. Orexo also appoints Novo Holdings CEO Kasim Kutay as head of its nomination committee.
BY MARTIN HAVTORN PETERSEN
The Swedish drug group Orexo, which counts Novo Holdings as its major shareholder, has offloaded one of its development programs to a newly founded company in its home country. This is according to a press release from Orexo.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo Holdings prepares for major US offensive
For abonnenter
Novo Holdings to use new investment platform
For abonnenter
Orexo earns million-dollar milestone from AstraZeneca
For abonnenter
